This is a working overview of research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-07-30 and is reviewed periodically as new material appears.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
== Enzyme function == Cyanophycinase is a carboxy terminal specific exopeptidase, meaning it catalyzes the cleavage of the carboxy terminal peptide bond of cyanophycin. It was hypothesized that cyanophycinase was a serine protease due to extreme inhibition of the enzyme when used with known serine protease inhibitors, such as DMSO. Site directed mutagenesis experiments confirmed that the enzyme is a serine protease and suggested that Ser 132 is the primary catalytic residue. Other key residues for specificity include Gln101, Asp172, Gln173, Arg178, Arg180 and Arg183 which form a conserved pocket adjacent to Ser 132. Kinetic characterization of the enzyme demonstrates that the enzyme displays Michaelis–Menten kinetics with a kcat of 16.5 s−1 and a kcat/KM of 7.5 × 106 M−1 s−1.
=== Electron shells === The Danish physicist Niels Bohr applied Max Planck's idea of quantization to the atom. He concluded that the energy levels of electrons were quantised: only a discrete set of stable energy states were allowed. Bohr then attempted to understand periodicity through electron configurations, surmising in 1913 that the outer electrons should be responsible for the chemical properties of the element. In 1913, he produced the first electronic periodic table based on a quantum atom. Bohr called his electron shells "rings" in 1913: atomic orbitals within shells did not exist at the time of his planetary model. Bohr explains in Part 3 of his famous 1913 paper that the maximum electrons in a shell is eight, writing, "We see, further, that a ring of n electrons cannot rotate in a single ring round a nucleus of charge ne unless n < 8." For smaller atoms, the electron shells would be filled as follows: "rings of electrons will only join if they contain equal numbers of electrons; and that accordingly the numbers of electrons on inner rings will only be 2, 4, 8." However, in larger atoms the innermost shell would contain eight electrons: "on the other hand, the periodic system of the elements strongly suggests that already in neon N = 10 an inner ring of eight electrons will occur." His proposed electron configurations for the atoms (shown to the right) mostly do not accord with those now known. They were improved further after the work of Arnold Sommerfeld and Edmund Stoner discovered more quantum numbers.
=== Recycling === When galvanised steel is fed into an electric arc furnace, the steel is melted but the zinc coating is vaporised and becomes furnace dust; an average steel mill generates tens of thousands of tonnes of dust a year with a zinc content of 15–35%. Zinc can recovered from the dust by a number of processes, predominantly the Waelz process (90% in 2014). Recycling zinc produces 6.5 tonnes of CO₂ equivalent per tonne of zinc, compared with an average of 3.64 tonnes in the mining process. A number of experimental processes aim to increase efficiency, reduce overall energy expenditure, and lower CO₂ production to less than that generated by mining. These include the rotary hearth treatment of pelletised zinc containing dust (Kimitsu works, Nippon Steel); the SDHL (Saage, Dittrich, Hasche, Langbein) process, an efficiency modification of the Waelz process; the "DK process" a modified blast furnace process producing pig iron and zinc (oxide) dust from blast furnace dusts, sludges and other wastes; and the PRIMUS process (multi-stage zinc volatilisation furnace).
Septoplasty is a corrective surgical procedure for nasal septum deviation in which the nasal septum is straightened. Tonsillectomy or adenoidectomy in an attempt to increase the size of the airway. Tonsillotomy Removal or reduction of parts of the soft palate and some or all of the uvula, such as uvulopalatopharyngoplasty (UPPP) or laser-assisted uvulopalatoplasty (LAUP). Modern variants of this procedure sometimes use radiofrequency waves to heat and remove tissue. Turbinectomy is a surgical procedure in which all or some of the turbinate bones are removed to relieve nasal obstruction. Reduction of the tongue base, either with laser excision or radiofrequency ablation. Genioglossus advancement, in which a small portion of the lower jaw that attaches to the tongue is moved forward, to pull the tongue away from the back of the airway. Hyoid suspension, in which the hyoid bone in the neck, another attachment point for tongue muscles, is pulled forward in front of the larynx. Maxillomandibular advancement Bariatric surgery (for morbid obesity) Hypoglossal nerve stimulation Radiofrequency ablation
In 2005–06, fragrance mix was the third-most-prevalent allergen in USA patch tests (11.5%). 'Fragrance' was voted Allergen of the Year in 2007 by the American Contact Dermatitis Society. An academic study in the United States published in 2016 has shown that "34.7 % of the population reported health problems, such as migraine headaches and respiratory difficulties, when exposed to fragranced products". The composition of fragrances is usually not disclosed in the label of the products, hiding the actual chemicals of the formula, which raises concerns among some consumers. In the United States, this is because the law regulating cosmetics protects trade secrets. In the United States, fragrances are regulated by the Food and Drug Administration if present in cosmetics or drugs, by the Consumer Product Safety Commission if present in consumer products. No pre-market approval is required, except for drugs. Fragrances are also generally regulated by the Toxic Substances Control Act of 1976 that "grandfathered" existing chemicals without further review or testing and put the burden of proof that a new substance is not safe on the EPA. The EPA, however, does not conduct independent safety testing but relies on data provided by the manufacturer. A 2019 study of the top-selling skin moisturizers found 45% of those marketed as "fragrance-free" contained fragrance. Cosmetics are regulated in the United Kingdom and the composition of products must be provided.
Sources: en.wikipedia.org
=== Binding of substrates and co-substrates === Binding of phosphorylated substrates to distinct regions of the C-lobe has previously been detected by binding of a tungstate derivative (as a phosphate analog). Instead of phospho-primed substrate also the C-terminal regulatory domain of CK1δ is able to bind to this position for the purpose of autoregulatory function. Binding of ATP is mainly mediated via the glycine-rich P-loop (L-12, bridging strands β1 and β2), forming the top cover of the WTP binding site, and the so-called catalytic loop (L-67). Conformational changes affecting the activation loop (L-9D) are related to regulation of kinase activity. When the activation loop moves out of the catalytic site the catalytically relevant DFG motif (Asp-149, Phe-150, and Gly-151) shifts to an internal position. The aspartate residue chelates a Mg2+ ion allowing proper binding and orientation of ATP. Another residue, which is essentially involved in the regulation of kinase activity, but also in forming interactions with small molecule inhibitors, is Met-82, the so-called gatekeeper residue. Directly located within the ATP binding pocket this residue controls access of small molecules to certain binding pockets (selectivity pockets) located beyond the position of the gatekeeper.
=== Hydrogen breath test === In a hydrogen breath test, the most accurate lactose intolerance test, after an overnight fast, 25 grams of lactose (in a solution with water) are swallowed. If the lactose cannot be digested, enteric bacteria metabolize it and produce hydrogen, which, along with methane, if produced, can be detected on the patient's breath by a clinical gas chromatograph or compact solid-state detector. The test takes about 2.5 hours to complete. If the hydrogen levels in the patient's breath are high, they may have lactose intolerance. This test is not usually done on babies and very young children, because it can cause severe diarrhea.
Record league victory: 9–0 v Loughborough, Second Division, 28 January 1899 v Accrington Stanley (away), Third Division North, 3 February 1934 Record cup victory: 6–0 v Blackpool, FA Cup first round, 20 January 1910 Record league defeat: 9–0 v Notts County, Second Division, 19 January 1927 Record cup defeat: 8–1 v Derby County, FA Cup first round, 30 January 1897 7–0 v Manchester United, EFL Cup third round, 17 September 2024 Most appearances: Barry Murphy, 569 Most goals scored for the club: Ernie Hine, 131 Most league goals scored in a season: Cecil McCormack, 33, 1950–51 Second Division Most international caps: Gerry Taggart, 35, Northern Ireland Record transfer fee received: £5,000,000 from Swansea City for Alfie Mawson (2017) Record transfer fee paid: £1,500,000 to Partizan Belgrade for Georgi Hristov (1997) and £1,500,000 to QPR for Mike Sheron (1999) Record attendance: 40,255 v Stoke City, FA Cup fifth round, 15 February 1936 Youngest ever Football League player: Reuben Noble-Lazarus, 15 years and 45 days Oldest player: Mike Pollitt, 41 years, 5 months and 30 days Most goals scored in a single game: 5; Frank Eaton v South Shields, 1927 Peter Cunningham v Darlington, 1933 Beaumont Asquith v Darlington, 1938 Cecil McCormack v Luton Town, 1950 Barnsley have spent more seasons and played more games at the second level of English football than any other team.
Dalbergia odorifera, fragrant rosewood or Chinese rosewood, is a species of true rosewood in the genus Dalbergia. It is a small or medium-sized tree, 10–15 metres (33–49 ft) tall. It is endemic to China and occurs in Fujian, Hainan, Zhejiang, and Guangdong.
=== Drug policy === As part of the US-led war on drugs, Peru has historically pursued a coca-eradication policy. However, during his electoral campaign, Pedro Castillo pledged to expel DEA agents from Peru. In April 2021, under then President Francisco Sagasti, coca eradication operations in the VRAEM were suspended. In September, following Castillo's inauguration, coca eradication was resumed in all areas except the VRAEM, which is the area with the most coca cultivation. Under the Vásquez cabinet, Interior Minister Luis Barranzuela was asked whether he ordered Coca eradication to be suspended in the VRAEM, which he denied. Barranzuela also said that the Interior Ministry has no influence on Devida, the agency in charge of anti-drug policy. Later, the Free Peru caucus proposed to legalize the commercialization and industrial cultivation of the coca leaf. Currently, coca leaf consumption is allowed for "traditional purposes." The proposed bill would also declare the coca leaf "the natural heritage of the nation." Prime Minister Mirtha Vásquez claimed that coca farmers are "fed up" with the permanent cycle of coca eradication and replantation. Vásquez stated that she would pursue binding agreements with legal coca producers while cracking down on drug trafficking. On 19 November 2021, the new Interior Minister Avelino Guillén pledged to increase the eradication of coca crops.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.